Senior leadership at M. D. Anderson Cancer Center (MDACC) is comprised of the President and 4 Vice Presidents representing basic, translational, clinical and prevention programs. These leaders are responsible for collaborations across programs, direction and strategic planning, oversight of shared resources, education, community outreach and budgetary oversight Over the past five years, Dr. John Mendelsohn has provided consistent and strong leadership as President of MDACC and PI of the CCSG. Dr. Robert Bast has continued to coordinate the Office of Translational Research and is Co-Pi of the CCSG, aiding Dr. Mendelsohn in coordinating Cancer Center Programs and Shared Resources. Dr. Maurie Markman serves as Vice President of Clinical Research, including leadership of the Clinical Trials Support Resource and the Protocol Review and Monitoring System. Dr. Raymond DuBois, who joined MDACC this year, serves as Provost. He will oversee all academic and research activities at MDACC. MDACC is currently recruiting for our next Vice President for Cancer Prevention.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Liu, Yihua; Weber, Zachary; San Lucas, F Anthony et al. (2018) Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. Gynecol Oncol 151:243-249
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Jensen, Garrett; Tao, Randa; Eng, Cathy et al. (2018) Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol 3:595-600
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Boddu, Prajwal; Borthakur, Gautam; Koneru, Mythili et al. (2018) Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369
Takahashi, Nobuaki; Chen, Hsing-Yu; Harris, Isaac S et al. (2018) Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003.e7
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105

Showing the most recent 10 out of 12418 publications